ABUS - Arbutus Biopharma Corp
IEX Last Trade
3.205
0.025 0.780%
Share volume: 39,857
Last Updated: Fri 27 Dec 2024 08:30:14 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$3.18
0.03
0.79%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-09 | 2023-03-02 | 2023-05-04 | 2023-08-03 | 2023-11-07 | 2024-03-05 | 2024-05-02 | |
| Assets | |||||||||
| Total Assets | 215.836 M | 203.801 M | 195.419 M | 191.224 M | 176.823 M | 158.641 M | 144.401 M | 150.290 M | |
| Current Assets | 157.791 M | 141.136 M | 151.139 M | 152.854 M | 158.800 M | 141.607 M | 132.027 M | 135.872 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 5.622 M | 4.583 M | 2.874 M | 3.462 M | 3.702 M | 5.256 M | 4.248 M | 4.493 M | |
| Short Term Investments | 5.622 M | 4.583 M | 2.874 M | 3.462 M | 3.702 M | 5.256 M | 4.248 M | 4.493 M | |
| Total Receivables | 1.970 M | 1.835 M | 1.352 M | 2.664 M | 2.614 M | 2.171 M | 1.776 M | 2.139 M | |
| Current Cash | 150.199 M | 134.718 M | 146.913 M | 146.728 M | 152.484 M | 134.180 M | 126.003 M | 129.240 M | |
| Total Non-current Assets | 58.045 M | 62.665 M | 44.280 M | 38.370 M | 18.023 M | 17.034 M | 12.374 M | 14.418 M | |
| Property Plant Equipment | 5.493 M | 5.241 M | 5.070 M | 4.853 M | 5.370 M | 5.033 M | 4.674 M | 4.414 M | |
| Other Assets | 180.000 K | 167.000 K | 103.000 K | 62.000 K | 11.000 K | 3.000 K | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 215.836 M | 203.801 M | 195.419 M | 191.224 M | 176.823 M | 158.641 M | 144.401 M | 150.290 M | |
| Total liabilities | 62.694 M | 58.284 M | 58.567 M | 47.309 M | 42.130 M | 39.304 M | 38.383 M | 35.653 M | |
| Total current liabilities | 29.824 M | 27.506 M | 32.857 M | 25.154 M | 24.529 M | 22.324 M | 22.487 M | 20.296 M | |
| Accounts Payable | 0.000 | 872.000 K | 3.520 M | 2.455 M | 1.044 M | 2.260 M | 3.223 M | 3.743 M | |
| Other liabilities | 30.782 M | 28.823 M | 23.895 M | 20.484 M | 15.955 M | 15.483 M | 14.553 M | 14.176 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 30.782 M | 28.823 M | 23.895 M | 20.484 M | 15.955 M | 15.483 M | 14.553 M | 14.176 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 153.142 M | 145.517 M | 136.852 M | 143.915 M | 134.693 M | 119.337 M | 106.018 M | 114.637 M | |
| Common stock | 148.750 M | 150.995 M | 155.584 M | 161.643 M | 166.063 M | 167.513 M | 168.622 M | 175.626 M | |
| Retained earnings | -1.164 B | -1.182 B | -1.204 B | -1.220 B | -1.237 B | -1.257 B | -1.277 B | -1.295 B |